000153077 001__ 153077
000153077 005__ 20240229120023.0
000153077 0247_ $$2doi$$a10.3389/fonc.2019.01458
000153077 0247_ $$2pmid$$apmid:31921698
000153077 0247_ $$2pmc$$apmc:PMC6933601
000153077 0247_ $$2altmetric$$aaltmetric:73044740
000153077 037__ $$aDKFZ-2020-00159
000153077 041__ $$aeng
000153077 082__ $$a610
000153077 1001_ $$aChen, Celine$$b0
000153077 245__ $$aCurrent and Future Treatment Strategies for Rhabdomyosarcoma.
000153077 260__ $$aLausanne$$bFrontiers Media$$c2019
000153077 3367_ $$2DRIVER$$aarticle
000153077 3367_ $$2DataCite$$aOutput Types/Journal article
000153077 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1579007722_29064$$xReview Article
000153077 3367_ $$2BibTeX$$aARTICLE
000153077 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153077 3367_ $$00$$2EndNote$$aJournal Article
000153077 520__ $$aRhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can be subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over the last four decades, there have been no significant improvements in clinical outcomes for advanced and metastatic RMS patients, underscoring a need for new treatment options for these groups. Despite significant advancements in our understanding of the genomic landscape and underlying biological mechanisms governing RMS that have informed the identification of novel therapeutic targets, development of these therapies in clinical trials has lagged far behind. In this review, we summarize the current frontline multi-modality therapy for RMS according to pediatric protocols, highlight emerging targeted therapies and immunotherapies identified by preclinical studies, and discuss early clinical trial data and the implications they hold for future clinical development.
000153077 536__ $$0G:(DE-HGF)POF3-899$$a899 - ohne Topic (POF3-899)$$cPOF3-899$$fPOF III$$x0
000153077 588__ $$aDataset connected to CrossRef, PubMed,
000153077 7001_ $$aDorado Garcia, Heathcliff$$b1
000153077 7001_ $$aScheer, Monika$$b2
000153077 7001_ $$0P:(DE-HGF)0$$aHenssen, Anton G$$b3
000153077 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2019.01458$$gVol. 9, p. 1458$$p1458$$tFrontiers in oncology$$v9$$x2234-943X$$y2019
000153077 909CO $$ooai:inrepo02.dkfz.de:153077$$pVDB
000153077 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000153077 9131_ $$0G:(DE-HGF)POF3-899$$1G:(DE-HGF)POF3-890$$2G:(DE-HGF)POF3-800$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000153077 9141_ $$y2019
000153077 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2017
000153077 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153077 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153077 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153077 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000153077 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000153077 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000153077 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000153077 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000153077 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153077 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153077 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153077 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000153077 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000153077 9201_ $$0I:(DE-He78)L201-20160331$$kL201$$lDKTK Berlin$$x0
000153077 980__ $$ajournal
000153077 980__ $$aVDB
000153077 980__ $$aI:(DE-He78)L201-20160331
000153077 980__ $$aUNRESTRICTED